Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Mirati Therapeutics, Lowers Price Target to $127

Citigroup analyst Yigal Nochomovitz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $208 to $127.
byBenzinga Newsdesk
July 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Yigal Nochomovitz maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $208 to $127.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts